Press

Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Mental Health Disorders

Jun 15 • 4 min read

Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders, is pleased to announce today the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area in Ontario. The Kitchen-waterloo location is the fifth Braxia…

Filament Health Cultivates 70th Variety of Psilocybin-containing Mushrooms At Vancouver Facility

Jun 14 • 1 min read

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) cultivated its 70th variety of psilocybin-containing mushrooms at its 3,500 square foot GMPcompliant facility in Metro Vancouver. Filament also announced the successful development of standardized, pharmaceutical grade ayahuasca extract, designed for oral administration by capsule or tablet. The drug product was manufactured using Filament’s proprietary processing…

Mindset Pharma Receives Notice of Allowance for Patent Application for Psilocin Derivatives

Jun 13 • 2 min read

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced that the United States Patent and Trademark Office (‘USPTO’) has issued a Notice of Allowance for Mindset’s patent application…

Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay

Jun 10 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA | FSE: HN3Q | OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has signed a research agreement with the University of Central Florida (UCF) Research Foundation to develop a saliva serotonin assay….

Tryp Therapeutics Announces Results of First Patient Dosed in Phase II Clinical Trial for Binge Eating Disorder

Jun 9 • 4 min read

Tryp Therapeutics, Inc. (CSE: TRYP | OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the initial data readout for the first patient dosed in its Phase II S.T.O.P. (Study of the Treatment of Overeating utilizing Psilocybin) trial. In collaboration with the University of Florida….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441